Antiviral combinations for severe influenza.
Jake Dunning1, J Kenneth Baillie2, Bin Cao3
1Centre for Respiratory Infection, National Heart and Lung Institute, Imperial College London, London, UK.
The Lancet. Infectious Diseases
|September 13, 2014
Summary
Combining antiviral drugs and immune modulators may improve influenza treatment, especially for severe cases and novel virus strains. Further clinical trials are needed to confirm the efficacy of these combination therapies.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Neuraminidase inhibitors can reduce severe influenza illness, but may fail with novel viruses and can promote drug resistance.
- Antiviral resistance is a concern, particularly in immunocompromised and critically ill patients.
- Host immune responses play a role in influenza pathogenesis.
Purpose of the Study:
- To review preclinical and clinical data on combination antiviral therapy for influenza.
- To evaluate combined antiviral and immunomodulator therapy for influenza.
- To identify promising combination strategies for severe influenza infections.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of data on antiviral combinations.
- Analysis of data on combined antiviral-immunomodulator therapies.
Main Results:
- Several antiviral combinations show promise for severe influenza in early studies.
- Combined antiviral-immunomodulator therapies are being explored.
- Data suggest potential benefits but require further substantiation.
Conclusions:
- Combination therapies, including antiviral and immunomodulatory approaches, may offer improved outcomes for influenza.
- Further well-designed clinical trials are essential to validate the efficacy of these combination strategies.
- Optimizing influenza treatment may involve multi-drug approaches targeting both the virus and the host response.
More Related Videos
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
54
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
54
01:27Influenza
70
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
70
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
665
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
665
01:29Subviral Agents
919
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
919
01:28Pneumonia IV: Management
1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
02:28Leaky Scanning
4.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
4.5K